Get started
Author

R. Leporati

Data analytics for real-world data integration in TKI-treated NSCLC patients using electronic health records
2025 · L. Mazzeo, F. Corso, et al. · ESMO Real World Data and Digital Oncology · 2
PDF
From Tumour to Bloodstream: Advancing PD ‐ L1 Testing With Liquid Biopsies in Non‐Small Cell Lung Cancer
2026 · R. Leporati, V. Callegari, et al. · Cytopathology
EP.13.05 Twice Daily Hyperfractionated vs Once Daily Normofractionated Chemo-Radiotherapy in LS-SCLC: A Monocentric Experience
2025 · A. Cappelli, A. Benini, et al. · Journal of Thoracic Oncology
1908P Clinical determinants of early mortality in patients with PD-L1 ≥50% non-small cell lung cancer treated with single-agent immunotherapy: A retrospective single-center study
2025 · L. Trudu, C. Petrangelo, et al. · Annals of Oncology
198P: Progression patterns and survival outcomes in patients with locally advanced NSCLC after chemo-radiotherapy and durvalumab: Insights into post-progression strategies from a single institution
2025 · R. Leporati, L. Mastrodomenico, et al. · Journal of Thoracic Oncology
PDF
EP.12A.05 Evaluation of the Role of VAF/cellularity as Proxy of Gene Aberration in EGFR Mutated Advanced NSCLC During Osimertinib
2024 · M. Brambilla, D. Lorenzini, et al. · Journal of Thoracic Oncology
201P Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: An international multicentric analysis
2024 · M.I. Gomez-Randulfe Rodriguez, C. Escriu, et al. · ESMO Open
68P OncoMutational ratio on ctDNA: A potential novel biomarker in NSCLC
2023 · P. Ambrosini, L. Provenzano, et al. · Journal of Thoracic Oncology
PDF
Works count: 8
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type